Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03238027 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors
A Phase 1 study of Solid Tumor and Locally Advanced Malignant Neoplasm, sponsored by Syndax Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 5
- Study locations
NCT03238027: Completed Phase 1 study of Solid Tumor and Locally Advanced Malignant Neoplasm, sponsored by Syndax Pharmaceuticals.
NCT03238027 is a Phase 1 study of Solid Tumor and Locally Advanced Malignant Neoplasm that has completed, run by Syndax Pharmaceuticals. The registered enrollment target is 45 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (80% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03238027, a Phase 1 study of Solid Tumor and Locally Advanced Malignant Neoplasm, has completed, sponsored by Syndax Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 5
- Study locations
Study Summary
A Phase 1 dose escalation study to determine if axatilimab as monotherapy and axatilimab in combination with a fixed dose of durvalumab will be sufficiently safe and well-tolerated at biologically active doses to warrant further investigation in patients with solid tumors.
Primary Outcome
All patients treated with axatilimab across all treatment arms (dosing levels) will have safety assessed in order to determine any dose-limiting toxicities (DLT)s.
Conditions Studied
Interventions
- DRUG Durvalumab
- DRUG Axatilimab
Study Locations (5)
Texas
- NEXT Oncology - San Antonio
- South Texas Accelerated Research Therapeutics - San Antonio
Arizona
- Honor Health - Scottsdale
Maryland
- Johns Hopkins University - Baltimore
Oregon
- Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2017-09-01 |
| Est. Completion | 2020-11-20 |
| Phase | Phase 1 |
What the finished NCT03238027 record still lists
NCT03238027 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (80% lower).
The record links to 4 conditions, with Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Durvalumab is the first listed.
NCT03238027 lists 5 locations in 4 states (Texas, Arizona, Maryland).
Frequently Asked Questions
What is clinical trial NCT03238027 about?
NCT03238027 is a clinical study titled "A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors". A Phase 1 dose escalation study to determine if axatilimab as monotherapy and axatilimab in combination with a fixed dose of durvalumab will be sufficiently safe and well-tolerated at biologically active doses to warrant further investigation in patients with solid tumors.
What is the current status of trial NCT03238027?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2017-09-01. Estimated completion is 2020-11-20.
What conditions does trial NCT03238027 study?
This clinical trial studies the following conditions: Solid Tumor, Locally Advanced Malignant Neoplasm, Metastatic Tumor, Unresectable Malignant Neoplasm.
What interventions are being tested in trial NCT03238027?
The interventions under investigation include: Durvalumab (DRUG), Axatilimab (DRUG).
Who is sponsoring clinical trial NCT03238027?
This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03238027 being conducted?
This trial has 5 study locations across Arizona, Maryland, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03238027's enrollment target sits among peer trials
45 133rd of 196 higher than 62 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI